CSIMarket
 
Jazz Pharmaceuticals Plc  (JAZZ)
Other Ticker:  
 
 
Price: $120.9000 $2.60 2.198%
Day's High: $121.586 Week Perf: 3.66 %
Day's Low: $ 118.13 30 Day Perf: -1.1 %
Volume (M): 1,529 52 Wk High: $ 147.98
Volume (M$): $ 184,904 52 Wk Avg: $129.55
Open: $118.13 52 Wk Low: $111.25



 Market Capitalization (Millions $) 8,222
 Shares Outstanding (Millions) 68
 Employees 1,720
 Revenues (TTM) (Millions $) 3,834
 Net Income (TTM) (Millions $) 415
 Cash Flow (TTM) (Millions $) 625
 Capital Exp. (TTM) (Millions $) 24

Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc is a bio-pharmaceutical company that primarily focuses on developing and commercializing innovative treatments for various medical conditions, including sleep disorders, oncology, and neurology. It was founded in 2003 and is headquartered in Dublin, Ireland.

The company's portfolio includes several marketed products, such as:

1. Xyrem: It is an FDA-approved medication for the treatment of the rare sleep disorder called cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy.

2. Erwinaze: It is a medication used in the treatment of acute lymphoblastic leukemia (ALL) to convert asparagine to aspartic acid, thereby starving tumor cells of asparagine.

3. Defitelio: It is a drug that is used in the treatment of rare, life-threatening, and rapidly progressing liver and lung conditions associated with stem cell transplant.

Jazz Pharmaceuticals has several drugs that are currently in the clinical trial phase for treating other medical conditions like resistant depression, fibromyalgia, and Parkinson's disease.

The company's revenue is generated primarily from the sale of its products, which are marketed and sold in the United States, Europe, and other regions. In 2020, Jazz Pharmaceuticals reported total corporate revenue of $2.3 billion.

Jazz Pharmaceuticals has a diverse team of approximately 2,200 employees worldwide who work together to develop, manufacture, and market its products. The company is committed to adhering to high ethical standards and ensures compliance with all legal and regulatory requirements.

Jazz Pharmaceuticals has received many awards and accolades for its efforts in the field of bio-pharmaceuticals, including the Pharma Marketing Award for its patient-focused marketing campaign for Xyrem. It has also been listed among the "Fastest Growing Companies" in Ireland and the United States.

Overall, Jazz Pharmaceuticals is a leading player in the bio-pharmaceutical industry with a focus on developing innovative treatments for various medical conditions. Its commitment to research, development, and high ethical standards has contributed to its success and growth over the years.


   Company Address: Fifth Floor, Waterloo Exchange Dublin 4 0
   Company Phone Number: 634-7800   Stock Exchange / Ticker: NASDAQ JAZZ
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Jazz Pharmaceuticals Plc

Jazz Pharmaceuticals Plc Faces Uncertainty Despite Positive Profit Numbers

Jazz Pharmaceuticals Plc: Weak Financial Performance Raises Concerns
Jazz Pharmaceuticals Plc, a major pharmaceutical preparations company, reported surprisingly positive profit numbers for the financial fourth quarter of 2023. However, a closer analysis reveals a much bleaker outlook for the company. Profits turned positive at $1.20 per share compared to a staggering loss of $4.75 per share in the same quarter a year ago. Although this may seem like a remarkable improvement, it is important to note that profits plummeted by a significant -43.71% from $2.14 per share in the preceding quarter.
The company's revenue also presents a cause for concern. It decreased substantially by -18.925% to $1.01 billion from $1.25 billion in the comparable quarter a year prior. While the sequential revenue grew by 4.094% from $972.14 million, this growth is not strong enough to indicate stability or a positive trend.

Jazz Pharmaceuticals Plc

Jazz Pharmaceuticals Plc Records Impressive 3.347% Surge in Revenues During Latest Fiscal Period

Jazz Pharmaceuticals plc, a major player in the pharmaceutical industry, has demonstrated impressive growth and financial performance in the recent quarter. In the period from July to September 2023, the company's income turned positive at $2.14 per share, compared to a loss of $0.31 per share during the same period last year. This marks a significant improvement and a boost of 40.79% in earnings per share (EPS) from the preceding reporting season.
Furthermore, Jazz Pharmaceuticals has shown a modest revenue increase of 3.347%, reaching $972.14 million compared to $940.65 million in the corresponding reporting period last year. Sequentially, the company experienced a 1.548% growth in revenue from $957.32 million. This impressive revenue growth outperforms the industry average, as the Major Pharmaceutical Preparations sector only saw a 2.06% rise in revenue for the same period.

Jazz Pharmaceuticals Plc

Jazz Pharmaceuticals Plc Surpasses Expectations with Phenomenal Profitability Surge in Q2 2023

Jazz Pharmaceuticals Plc, a major player in the pharmaceutical industry, delivered strong profitability advances in the financial second quarter of 2023. Despite a slow rise in revenue, the company saw significant growth in its earnings per share (EPS) and net earnings.
In the second quarter of 2023, Jazz Pharmaceuticals saw its EPS soar by an impressive 176.36% to reach $1.52 per share. This is a significant improvement compared to the same period a year ago when the EPS stood at $1.04 per share. Additionally, the company's bottom-line earnings for the quarter increased by a staggering 201.28% to reach $104.438 million, up from $34.665 million in the second quarter of 2022.

Jazz Pharmaceuticals Plc

Jazz Pharmaceuticals Plc: Revenue Plummets by 41%, But Bounces Back with a Profitable Turnaround

Jazz Pharmaceuticals Plc is facing a challenge in terms of revenue per employee, as it fell on a trailing twelve month basis to $2,334,002. Despite this decline, the productivity of the company's employees remained above the company average. The company currently has 1,720 employees, but among its peers in the Healthcare sector, employees of 18 other companies have achieved higher revenue per employee.
The overall ranking of Jazz Pharmaceuticals Plc has also deteriorated compared to the fourth quarter of 2022, falling to 18. However, there is good news for the company in terms of the first quarter of the 2023 earnings season. JAZZ reported a turnaround to profits, with EPS of $1.04 per share compared to $-11.42 a year before. The income per share also turned positive, rising from $-4.75 per share in the prior reporting period.






 

Jazz Pharmaceuticals Plc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Jazz Pharmaceuticals Plc does not provide revenue guidance.

Earnings Outlook
Jazz Pharmaceuticals Plc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com